Loading...
XSHG600513
Market cap447mUSD
Jan 08, Last price  
11.48CNY
1D
9.96%
1Q
23.71%
Jan 2017
-14.52%
Name

JIANGSU LIANHUAN PHARMACEUTICAL CO. LTD

Chart & Performance

D1W1MN
XSHG:600513 chart
P/E
24.27
P/S
1.51
EPS
0.47
Div Yield, %
1.31%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
16.36%
Revenues
2.17b
+11.20%
181,193,511172,993,634166,239,532194,783,184225,372,855259,893,808289,442,020324,214,970325,358,991623,302,812668,688,165642,432,917604,860,656689,099,3491,019,238,7321,290,332,6621,386,038,5801,645,816,3991,955,156,7812,174,100,304
Net income
135m
-4.50%
7,257,7237,571,2268,099,83710,146,70213,144,74317,198,97420,334,21724,507,89428,656,15938,326,09443,995,34050,114,96862,690,17170,547,32073,556,81779,730,500103,001,877118,839,366141,370,528135,008,519
CFO
161m
+25.95%
3,392,9923,822,50910,143,7448,033,39117,441,74913,831,2708,425,76623,995,92616,941,25237,173,07969,500,06962,117,30470,285,0673,635,6970091,936,547138,344,527127,590,488160,701,795
Dividend
May 24, 20240.15 CNY/sh
Earnings
Mar 28, 2025

Profile

Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells chemical raw materials, preparations, and organic intermediates in China. The company offers cardiovascular, anti-allergic, urinary, anti-infective, and immunomodulatory products. The company was founded in 2000 and is headquartered in Yangzhou, China.
URL
http://www.lhpharma.com
IPO date
Mar 19, 2003
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,174,100
11.20%
1,955,157
18.80%
Cost of revenue
1,868,372
1,633,243
Unusual Expense (Income)
NOPBT
305,729
321,914
NOPBT Margin
14.06%
16.46%
Operating Taxes
23,692
22,611
Tax Rate
7.75%
7.02%
NOPAT
282,037
299,303
Net income
135,009
-4.50%
141,371
18.96%
Dividends
(43,072)
(35,893)
Dividend yield
1.35%
1.34%
Proceeds from repurchase of equity
(6,259)
BB yield
0.20%
Debt
Debt current
591,762
587,711
Long-term debt
86,825
49,650
Deferred revenue
3,934
2,351
Other long-term liabilities
592
368
Net debt
385,570
301,748
Cash flow
Cash from operating activities
160,702
127,590
CAPEX
(200,665)
Cash from investing activities
(184,694)
Cash from financing activities
(35,098)
76,923
FCF
50,133
61,190
Balance
Cash
281,380
330,647
Long term investments
11,637
4,966
Excess cash
184,312
237,854
Stockholders' equity
1,260,049
1,151,901
Invested Capital
2,012,199
1,779,730
ROIC
14.88%
18.21%
ROCE
13.89%
15.92%
EV
Common stock shares outstanding
287,252
285,456
Price
11.14
18.64%
9.39
-2.80%
Market cap
3,199,989
19.38%
2,680,434
-2.80%
EV
3,748,680
3,129,291
EBITDA
362,209
362,723
EV/EBITDA
10.35
8.63
Interest
26,688
25,183
Interest/NOPBT
8.73%
7.82%